US FDA Allows Supplement Firms More Time To Submit NDI Notifications, And For It To Respond
Executive Summary
More time for notifications than current deadline of at least 75 days before NDI-containing product is offered for sale in US doesn’t solve problems with FDA’s management of NDI regulation, say trade groups.
You may also be interested in...
US FDA Narrows Guidance For New Dietary Ingredient Notifications To Magnify Compliance
Draft guidances in 2011 and 2016 were met with widespread questions and opposition from supplement industry, joined by then-senators who had were chief authors of DSHEA. FDA in 2023 said it would provide separate guidance documents on “discrete sections” of the requirement.
Tianeptine Rings Latest Unapproved Drug Alarm, Followed By Echo About Lack Of FDA Regulation
Tianeptine isn’t approved as drug in US nor allowed for use as dietary ingredient or food additive. FDA has warned multiple firms selling tianeptine-containing products and federal prosecutors recently announced guilty plea from man who sold the drug to consumers.
The Dietary Supplement Market US FDA Is Regulating Isn’t Your 1994 DSHEA Version
“In the last 30 years, we've seen this sort of explosion, and it's not just more products and more sales. We're talking about more complex products,” says Cara Welch, FDA Office of Dietary Supplement Programs director. “Today's products are not the products from 1994.”